Compare Lucid Group Inc (LCID) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs McKesson Corporation — how do they compare? Lucid Group Inc trades at $7.32 (market cap $2.77B), while McKesson Corporation trades at $832.45 (market cap $97.35B). The key difference: McKesson Corporation is far larger — about 35.1× Lucid Group Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| LCID | MCK | |
|---|---|---|
Market Cap | $2.77B | $97.35B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.30 | $995.69 |
52-Week Low | $4.62 | $659.01 |
Enterprise Value | $5.24B | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $7.32, down 0.54% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported a net loss of $2.70 billion on $1.35 billion revenue in 2025, with negative profit margins and cash flow. Recent news highlights multiple class action lawsuits filed against the company, alleging securities fraud between February and April 2026.
The outlook remains challenged by persistent losses and high cash burn, though the consensus price target of $10.50 suggests potential upside. Key risks include ongoing litigation, competitive pressures in the EV market, and the need for additional financing to sustain operations amid negative cash flows.
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
